University Of Texas Aeglea Bio Therapeutics, Inc. Transaction History

University Of Texas

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$6.03 - $7.95 $144,117 - $190,005	-23,900 Reduced 8.87%	245,678 $1.95 Million
Q2 2021 Aug 06, 2021	SELL	$6.32 - $8.38 $63,832 - $84,638	-10,100 Reduced 3.61%	269,578 $1.88 Million
Q2 2020 Aug 04, 2020	SELL	$4.01 - $11.04 $172,349 - $474,499	-42,980 Reduced 13.32%	279,678 $2.59 Million
Q4 2019 Feb 10, 2020	SELL	$7.23 - $8.55 $91,249 - $107,909	-12,621 Reduced 3.76%	322,658 $2.47 Million
Q3 2018 Nov 13, 2018	SELL	$8.24 - $11.0 $44,496 - $59,400	-5,400 Reduced 1.59%	335,279 $3.21 Million
Q2 2018 Aug 07, 2018	SELL	$7.87 - $10.89 $1.45 Million - $2.01 Million	-184,250 Reduced 35.1%	340,679 $3.6 Million
Q3 2017 Nov 13, 2017	BUY	$2.91 - $4.93 $1.53 Million - $2.59 Million	524,929	524,929 $2.59 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of University Of Texas, based on Form 13F filings with the SEC.

Stay updated on University Of Texas with notifications on news.